Welcome to our dedicated page for Revolution Medicines news (Ticker: RVMD), a resource for investors and traders seeking the latest updates and insights on Revolution Medicines stock.
Revolution Medicines, Inc. develops targeted oncology therapies for patients with RAS-addicted cancers. Company news centers on its RAS(ON) inhibitor pipeline, including daraxonrasib, a RAS(ON) multi-selective inhibitor, and selective programs such as elironrasib, zoldonrasib and RMC-5127.
Recurring updates cover clinical data in pancreatic ductal adenocarcinoma, non-small cell lung cancer and other RAS-mutant solid tumors, presentations at oncology meetings, scientific publications, regulatory interactions and trial-stage progress. Revolution Medicines also reports quarterly financial results, financing activity and corporate progress tied to research and development, potential commercialization planning and its broader RAS(ON) discovery platform.
Revolution Medicines (Nasdaq: RVMD) reported Q4 and full-year 2025 results and clinical progress on Feb 25, 2026. The company holds $2.0 billion in cash and received a $250 million royalty tranche, with $1.75 billion more committed. R&D and G&A rose materially; net loss was $364.9M in Q4 and $1.1B for 2025. Full-year 2026 GAAP operating expense guidance is $1.6–1.7B.
Clinical highlights: RASolute 302 pivotal readout expected in H1 2026; five ongoing Phase 3 trials and three planned; initiated RASolute 305 and advanced RMC-5127 into first-in-human dosing. Zoldonrasib received FDA Breakthrough Therapy designation for G12D NSCLC.
Revolution Medicines (Nasdaq: RVMD) said CEO Mark A. Goldsmith, M.D., Ph.D., will take part in a fireside chat at the TD Cowen 46th Annual Health Care Conference on March 3, 2026 at 9:50 a.m. ET.
According to the company, a live webcast will be available and a replay will remain on the company website for at least 14 days.
Revolution Medicines (Nasdaq: RVMD) will report fourth quarter and full year 2025 financial results on Wednesday, February 25, 2026 after market close. A senior management webcast will begin at 4:30 p.m. ET (1:30 p.m. PT) to discuss results and corporate progress. A replay will be available on the company website for at least 14 days.
Revolution Medicines (Nasdaq: RVMD) announced that Mark A. Goldsmith, M.D., Ph.D., CEO and chairman, will participate in a fireside chat at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11 at 9:30 a.m. ET.
According to the company, the session will be webcast live and a replay will be available on the company's investor website for at least 14 days following the event.
Revolution Medicines (NASDAQ:RVMD) announced dosing of the first patient in the first-in-human trial RMC-5127-001 (NCT07349537), evaluating RMC-5127, a RAS(ON) G12V-selective inhibitor.
The open-label trial will assess safety, tolerability, pharmacokinetics and preliminary antitumor activity as monotherapy and in combination in patients with RAS G12V–mutated PDAC, CRC and NSCLC. RMC-5127 is the company’s fifth disclosed mutant-selective RAS(ON) inhibitor and fourth clinical-stage program, targeting an estimated ~48,000 U.S. patients diagnosed annually with RAS G12V–driven cancers.
Revolution Medicines (Nasdaq: RVMD) announced that the U.S. FDA granted Breakthrough Therapy Designation to zoldonrasib for adults with KRAS G12D-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) previously treated with anti-PD-1/PD-L1 therapy and platinum chemotherapy. The designation is based on data from the monotherapy cohort of the Phase 1 RMC-9805-001 trial, which demonstrated encouraging antitumor activity and acceptable safety and tolerability. Zoldonrasib is a tri-complex RAS(ON) G12D-selective covalent inhibitor that binds cyclophilin A. This is the first Breakthrough Therapy Designation for an investigational drug specifically targeting RAS G12D in NSCLC and follows prior designations for the company's daraxonrasib and elironrasib.
Revolution Medicines (Nasdaq: RVMD) said CEO and chairman Mark A. Goldsmith, M.D., Ph.D. will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 10:30 a.m. PT.
The presentation will be available via live webcast at the company's investor events page and a replay will be posted on the website for at least 14 days after the live presentation.
Revolution Medicines (NASDAQ:RVMD) announced on Dec 18, 2025 that the first patient was randomized in RASolute 304, a global, open-label Phase 3 trial of daraxonrasib in resectable pancreatic ductal adenocarcinoma (PDAC) after surgery and perioperative chemotherapy.
RASolute 304 plans to enroll approximately 500 patients with oncogenic RAS mutations and will evaluate whether daraxonrasib improves disease-free survival versus observation; secondary endpoints include overall survival, safety, and tolerability. Daraxonrasib is being evaluated in four global Phase 3 trials, including three in PDAC and one in RAS mutant non-small cell lung cancer.
Revolution Medicines (Nasdaq: RVMD) reported Q3 2025 financial results and clinical progress on RAS(ON) inhibitors.
Clinical: RASolute 302 enrollment for daraxonrasib in previously treated PDAC is winding down with an expected data readout in 2026; RASolute 303 (first-line metastatic PDAC) remains on track to start in 2025; RASolute 304 (adjuvant resectable PDAC) has been initiated. Daraxonrasib holds FDA Breakthrough Therapy, Orphan Drug designation and a Commissioner’s National Priority Voucher. New trials for zoldonrasib, elironrasib and RMC-5127 are planned in 2026–2026 Q1.
Financial: Cash and marketable securities were $1.93B at Sept 30, 2025, including a $250M royalty tranche and $1.75B committed; Q3 R&D $262.5M, G&A $52.8M, net loss $305.2M; reiterated FY2025 GAAP net loss guidance of $1.03B–$1.09B. Company announced senior commercial and development hires and held a webcast on Nov 5, 2025.
Revolution Medicines (Nasdaq: RVMD) announced that CEO and chairman Mark A. Goldsmith, M.D., Ph.D. will participate in two investor conference fireside chats in November 2025.
Event details: Guggenheim Healthcare Innovation Conference fireside chat on Tuesday, November 11, 2025 at 9:00 a.m. ET, and Jefferies Global Healthcare Conference fireside chat on Tuesday, November 18, 2025 at 9:30 a.m. GMT. Live webcasts and archived replays will be available at the company investor events page, with replay access for at least 14 days.